These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26412073)

  • 41. The salt-inducible kinases inhibitor HG-9-91-01 exhibits antidepressant-like actions in mice exposed to chronic unpredictable mild stress.
    Huang J; Fan H; Chen YM; Wang CN; Guan W; Li WY; Shi TS; Chen WJ; Zhu BL; Liu JF; Jiang B
    Neuropharmacology; 2023 Apr; 227():109437. PubMed ID: 36702294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides.
    Werner FM; Coveñas R
    Curr Pharm Des; 2019; 25(4):388-395. PubMed ID: 30969164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of the PACAP signaling system in depression.
    Pinhasov A; Nesher E; Gross M; Turgeman G; Kreinin A; Yadid G
    Curr Pharm Des; 2011; 17(10):990-1001. PubMed ID: 21524254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.
    Noordam R; Avery CL; Visser LE; Stricker BH
    Pharmacogenomics; 2016 Jun; 17(9):1029-40. PubMed ID: 27248517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [New perspectives of the mechanism of action of antidepressants arised from genomic theory of depression].
    Cereseto M; Ferrero A
    Vertex; 2003; 14(51):30-5. PubMed ID: 12690407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Agmatine, a potential novel therapeutic strategy for depression.
    Freitas AE; Neis VB; Rodrigues ALS
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1885-1899. PubMed ID: 27836390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
    du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors associated with antidepressant use in depressed and non-depressed community-dwelling elderly: the three-city study.
    Soudry A; Dufouil C; Ritchie K; Dartigues JF; Tzourio C; Alpérovitch A
    Int J Geriatr Psychiatry; 2008 Mar; 23(3):324-30. PubMed ID: 17907265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.
    Sagud M; Nikolac Perkovic M; Vuksan-Cusa B; Maravic A; Svob Strac D; Mihaljevic Peles A; Zivkovic M; Kusevic Z; Pivac N
    Psychopharmacology (Berl); 2016 Sep; 233(17):3259-67. PubMed ID: 27356518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Milnacipran versus other antidepressive agents for depression.
    Nakagawa A; Watanabe N; Omori IM; Barbui C; Cipriani A; McGuire H; Churchill R; Furukawa TA
    Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD006529. PubMed ID: 19588396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Leptin in depression: a potential therapeutic target.
    Ge T; Fan J; Yang W; Cui R; Li B
    Cell Death Dis; 2018 Oct; 9(11):1096. PubMed ID: 30367065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding the genetic aspects of resistance to antidepressants treatment.
    Alqahtani AM; Kumarappan C; Kumar V; Srinivasan R; Krishnaraju V
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7784-7795. PubMed ID: 32744705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Ketamine Antidepressant Story: New Insights.
    Alshammari TK
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33297563
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
    Chaki S; Fukumoto K
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response.
    Derosa S; Misztak P; Mingardi J; Mazzini G; Müller HK; Musazzi L
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jan; 128():110871. PubMed ID: 37793481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging drugs for major depressive disorder.
    Connolly KR; Thase ME
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
    Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD
    Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OX2R activation induces PKC-mediated ERK and CREB phosphorylation.
    Guo Y; Feng P
    Exp Cell Res; 2012 Oct; 318(16):2004-13. PubMed ID: 22652455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Antidepressants, stressors and the serotonin 1A receptor].
    Kirilly E; Gonda X; Bagdy G
    Neuropsychopharmacol Hung; 2015 Jun; 17(2):81-9. PubMed ID: 26192901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.